Trial Radar KI | ||
|---|---|---|
Die klinische Studie NCT07490860 für Lungenkarzinom ist noch nicht rekrutierend. In der Kartenansicht des Klinische Studien Radar und den KI-Entdeckungstools finden Sie alle Details. Oder stellen Sie hier Ihre Fragen. | ||
Eine Studie entspricht den Filterkriterien
Kartenansicht
A Restorative Justice-Based Lung Cancer Screening Decision-Making Support Intervention Tailored for Black Individuals to Increase Lung Cancer Screening Among Black Community Members, RESTORE Trial 57
Die Details der klinischen Studie sind hauptsächlich auf Englisch verfügbar. Trial Radar KI kann jedoch helfen! Klicken Sie einfach auf 'Studie erklären', um die Informationen zur Studie in der ausgewählten Sprache anzuzeigen und zu besprechen.
Die klinische Studie NCT07490860 ist eine interventionsstudie zur Untersuchung von Lungenkarzinom und hat den Status noch nicht rekrutierend. Der Start ist für 1. Juli 2026 geplant, bis 57 Teilnehmer aufgenommen werden. Durchgeführt von Fred Hutchinson Cancer Center wird der Abschluss für 31. Dezember 2026 erwartet. Die Daten von ClinicalTrials.gov wurden zuletzt am 24. März 2026 aktualisiert.
Kurzbeschreibung
This clinical trial develops and studies whether a restorative justice-based lung cancer screening (LCS) decision-making support intervention tailored for Black individuals increases LCS among Black community members. Lung cancer remains the leading cause of cancer deaths among Black men and women. LCS with yearly low-dose chest computed tomography (CT) is recommended for people with current or recent tobacco use (wi...Mehr anzeigen
Ausführliche Beschreibung
OUTLINE: Participants are assigned to 1 of 2 aims.
AIM 1: Participants attend community advisory board (CAB) meetings over 60 minutes on study in support of the co-development and adaptation of the restorative justice-based LCS decision-making support intervention.
AIM 2: Participants attend an in-person restorative justice-based LCS decision-making support session over 2-3 hours on study.
After completion of stud...
Mehr anzeigenOffizieller Titel
Integrating Restorative Practices to Enhance Shared Decision-Making and Uptake of Lung Cancer Screening in Black Community Members (RESTORE)
Erkrankungen
LungenkarzinomWeitere Studien-IDs
NCT-Nummer
Studienbeginn (tatsächlich)
2026-07-01
Zuletzt aktualisiert
2026-03-24
Studienende (vorauss.)
2026-12-31
Geplante Rekrutierung
57
Studientyp
Interventionsstudie
PHASE
Nicht zutreffend
Status
Noch nicht rekrutierend
Primäres Ziel
Screening
Zuteilungsmethode
Nicht randomisiert
Interventionsmodell
Einarmige Studie
Verblindung
Keine (offene Studie)
Studienarme/Interventionen
| Teilnehmergruppe/Studienarm | Intervention/Behandlung |
|---|---|
Keine InterventionAim 1: Community advisory board (CAB) meetings Participants attend CAB meetings over 60 minutes on study in support of the co-development and adaptation of the restorative justice-based LCS decision-making support intervention. | Nicht zutreffend |
ExperimentellAim 2: Lung cancer screening (LCS) decision-making support session (intervention) Participants attend an in-person restorative justice-based LCS decision-making support session over 2-3 hours on study. | Bildungsintervention Attend LCS decision-making support session Umfrageverwaltung Ancillary studies Interview Ancillary studies Überprüfung elektronischer Gesundheitsakten Ancillary studies |
Hauptergebnismessungen
Nebenergebnismessungen
| Ergebnismessung | Beschreibung der Messung | Zeitrahmen |
|---|---|---|
Intervention acceptability | Assessed using the Acceptability of Intervention Measure (AIM). The AIM will be summarized and presented as a range of scores from 1 (low acceptability/appropriateness) to 5 (high acceptability/appropriateness). | At post-intervention (Day 1) |
Lung cancer screening knowledge | Will be assessed using the Lung Cancer Screening Knowledge 7 question score. Pre- and post-intervention responses will be compared via Chochran-Mantel-Haenszel and Friedman tests. | At pre- and post-intervention (both on Day 1) |
| Ergebnismessung | Beschreibung der Messung | Zeitrahmen |
|---|---|---|
Readiness to screen | Will be assessed using the Lung Cancer Screening Health Belief Scales. Participant responses will be summarized with the median and range of scores at pre- and post-intervention. | At pre- and post-intervention (both on Day 1) |
Medical mistrust | Will be assessed using the Discrimination in Medical Setting and Group-Based Medical Mistrust scale. Participant responses will be summarized with the median and range of scores at pre- and post-intervention. | At pre- and post-intervention (both on Day 1) |
Perceived smoking-related stigma | Will be assessed using the Cataldo Lung Cancer Stigma Scale: smoking-related subscale. Participant responses will be summarized with the median and range of scores at pre- and post-intervention. | At pre- and post-intervention (both on Day 1) |
Shared decision-making (SDM) process | Will be assessed using the Shared Decision Making Questionnaire. Participant responses will be summarized with the median and range of scores, with 0 indicating no SDM behavior and 100 indicating ideal SDM behavior. | At post-intervention (Day 1) |
Completion of chest computed tomography (CT) | Will assess completion of chest CT within 90 days post-intervention with no comparison. | Up to 90 days post-intervention |
Intervention acceptability and refinement | Will recruit a subset of participants to participate in a semi-structured interview post-intervention to gain an in-depth understanding of intervention acceptability and intervention refinement, including participant perspectives about the integration of restorative justice-based lung cancer screening decision-making support. Qualitative interview data will be analyzed using a mixed inductive-deductive approach to thematic analysis. | At 90 days post-intervention |
Teilnahme-Assistent
Eignungskriterien
Zugelassene Altersgruppen
Erwachsene, Ältere Erwachsene
Mindestalter
18 Years
Zugelassene Geschlechter
Alle
Akzeptiert gesunde Freiwillige
Ja
- AIM 1: At least 18 years of age
- AIM 1: Individuals who represent LCS-eligible patients, serve as members of Black/African American (AA)-serving community-based organizations (CBOs), and represent key providers, public health, nursing, and medical staff stakeholders
- AIM 2: Identify as Black or African American
- AIM 2: Between ages 50-77
- AIM 2: Self-reported 20-pack year smoking history
- AIM 2: Ongoing commercial tobacco use within the past 15 years
- AIM 2: Proficiency in the English language
- AIM 1: Under 18 years of age
- AIM 1: Non-English speaking community advisory board (CAB) members
- AIM 1: Inability to read written English
- AIM 2: Has a documented chest CT within the past one year
- AIM 2: Personal history of lung cancer or symptoms associated with lung cancer
Fred Hutchinson Cancer Center- AstraZeneca
- Go2 Foundation
Zentrale Studienkontakte
Kontakt: Matthew Triplette, MD, MPH, 206-667-6335, [email protected]
1 Studienstandorte in 1 Ländern
Washington
Fred Hutch/University of Washington Cancer Consortium, Seattle, Washington, 98109, United States
Matthew Triplette, MD, MPH, Kontakt, 206-667-6335, [email protected]
Matthew Triplette, MD, MPH, Hauptprüfer